Higher-dose proton radiation for stage III non-small-cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot enrolls adults with stage III non-small-cell lung cancer who will receive higher-dose intensity-modulated proton therapy (IMPT-74) together with standard chemotherapy and planned adjuvant durvalumab. Treatment includes induction chemotherapy (cisplatin or carboplatin plus pemetrexed), concurrent cisplatin plus docetaxel with escalated proton radiotherapy, and adjuvant durvalumab, with two extra clinic follow-ups and additional blood draws to monitor immune cells. The primary questions are whether severe radiotherapy toxicities requiring hospitalization remain within acceptable limits and to obtain a rough estimate of the treatment effect. Eligibility requires that the majority of the primary tumor volume lie outside the mediastinal planning-risk volume to allow safe dose escalation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* WHO performance score 0-2
* Histologically proven stage III NSCLC
* Planned for CCRT and adjuvant immunotherapy (intention to treat)
* Primary tumour volume outside of mediastinal PRV (i.e., mediastinal envelope + 5 mm) ≥60% of total primary tumour volume (true for 75% of patients in preliminary analysis), for sufficient dose escalation

Exclusion Criteria:

* Chemotherapy not given concurrently with radiotherapy
* Upfront decision that adjuvant immunotherapy is not possible
* Primary tumour overlapping ≥40% with mediastinal PRV
* Unable or unwilling to understand the information on trial-related topics, to give informed consent or to fill out quality-of-life questionnaires

Where it's running

• Umcg
  Groningen, Netherlands Recruiting

Study contacts

• Principal investigator: R. Wijsman, MD PhD — University Medical Center Groningen
• Study coordinator: A. Hessels, MD PhD
• Email: a.c.hessels@umcg.nl
• Phone: 06-25648774

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Multidisciplinary treatment planning for older people with lung cancer

  We will test a team-based approach that uses geriatric assessments to create personalized treatment plans for people aged 60–90 with newly diagnosed lung cancer to see if it improves 3-year progression-free survival compared with past patients.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07509333

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Intratumoral injection of N17350 in advanced solid tumors

  Aims to see if injected N17350 can shrink or control tumors in adults with advanced solid cancers who have few other options.

  Recruiting at 7 sites Phase 1/2 Onchilles Pharma Inc · Los Angeles, California and 8 other locations · NCT07339176

• Clinical outcomes of amivantamab-based treatment for advanced EGFR-mutated non-small cell lung cancer in everyday care.

  This project will see how amivantamab-containing treatments work for people with advanced non-small cell lung cancer who have common EGFR mutations.

  Recruiting at 90 sites Janssen Research & Development, LLC · Graz and 89 other locations · NCT07230691

• PF-08634404 combined with other cancer medicines for advanced non-small cell lung cancer

  This will test whether PF-08634404 given with other cancer medicines is safe and can help adults with advanced or metastatic non-small cell lung cancer.

  Recruiting at 85 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 103 other locations · NCT07227298

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.